Arrowstreet Capital’s Acorda Therapeutics ACOR Stock Holding History

Arrowstreet Capital’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,388	Closed	-$148K	–	2603
2020 Q3	$148K	Sell	2,388 -2,480	-51%	-$187K	﹤0.01%	2231
2020 Q2	$429K	Buy	+4,868	New	+$515K	﹤0.01%	2006
2020 Q1	–	Sell	-1,198	Closed	-$293K	–	2191
2019 Q4	$293K	Buy	+1,198	New	+$302K	﹤0.01%	1577
2019 Q2	–	Sell	-179	Closed	-$286K	–	1794
2019 Q1	$286K	Sell	179 -38	-18%	-$68.5K	﹤0.01%	1586
2018 Q4	$405K	Buy	217 +86	+66%	+$187K	﹤0.01%	1141
2018 Q3	$310K	Sell	131 -94	-42%	-$291K	﹤0.01%	974
2018 Q2	$775K	Buy	+225	New	+$689K	﹤0.01%	853
2016 Q4	–	Sell	-262	Closed	-$656K	–	2645
2016 Q3	$656K	Buy	+262	New	+$782K	﹤0.01%	1175
2016 Q2	–	Sell	-413	Closed	-$1.31M	–	1554
2016 Q1	$1.31M	Sell	413 -10	-2%	-$41.5K	0.01%	908
2015 Q4	$2.17M	Buy	+423	New	+$1.85M	0.01%	781
2015 Q2	–	Sell	-1,054	Closed	-$4.21M	–	1324
2015 Q1	$4.21M	Buy	1,054 +785	+292%	+$3.6M	0.03%	449
2014 Q4	$1.32M	Buy	+269	New	+$1.15M	0.01%	827
2014 Q1	–	Sell	-857	Closed	-$3M	–	1394
2013 Q4	$3M	Buy	+857	New	+$3.34M	0.02%	565

Other funds holding ACOR

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Arrowstreet Capital's ACOR Position: Q4 2020 in Review

Arrowstreet Capital sold out of Acorda Therapeutics (ACOR) in Q4 2020, closing a stake of 2,388 shares — an estimated $148K sold.

Arrowstreet Capital first reported a position in ACOR in Q4 2013 and held it in 13 quarters. The position peaked at $4.21M in Q1 2015. 47 funds tracked by Wall St. Rank hold ACOR as of Q4 2020.

Arrowstreet Capital reported no remaining Acorda Therapeutics position as of Q4 2020 after selling out during the quarter.
Arrowstreet Capital sold 2,388 Acorda Therapeutics shares in Q4 2020, an estimated $148K.
Arrowstreet Capital first reported a position in Acorda Therapeutics in Q4 2013 and held it in 13 quarters.
Arrowstreet Capital's Acorda Therapeutics position peaked at $4.21M in Q1 2015.
47 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.